DT vs. MRNA

Last updated Jun 13, 2026

DT (Dynatrace, Inc.) and MRNA (Moderna, Inc.) are both stocks. DT operates in Software - Application (Technology), while MRNA operates in Biotechnology (Healthcare). Over the past 5 years, DT returned -5.97%/yr vs -25.59%/yr for MRNA. At a 0.24 correlation, their price movements are largely independent.

Performance

DT vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Dynatrace, Inc. (DT) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DT achieves a -5.98% return, which is significantly lower than MRNA's 69.24% return.

DT

• 1D: 0.94%
• 1M: 6.23%
• YTD: -5.98%
• 6M: -11.49%
• 1Y: -23.16%
• 3Y*: -7.55%
• 5Y*: -5.97%
• 10Y*: —

MRNA

• 1D: 0.54%
• 1M: 1.77%
• YTD: 69.24%
• 6M: 69.42%
• 1Y: 87.14%
• 3Y*: -26.94%
• 5Y*: -25.59%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

DT vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
DT Dynatrace, Inc.	-5.98%	-20.26%	-0.62%	42.79%	-36.54%	39.47%	71.03%	-0.78%
MRNA Moderna, Inc.	69.24%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	49.31%

Correlation

The correlation between DT and MRNA is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.08
Correlation (3Y) Calculated over the trailing 3-year period	0.15
Correlation (5Y) Calculated over the trailing 5-year period	0.27
Correlation (All Time) Calculated using the full available price history since Aug 1, 2019	0.24

The correlation between DT and MRNA shifts across timeframes, from 0.08 (1 year) to 0.27 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap DT : $12.18B MRNA : $19.71B
EPS DT : $0.73 MRNA : -$8.16
PS Ratio DT : 6.11 MRNA : 8.78
PB Ratio DT : 4.66 MRNA : 2.66
Total Revenue (TTM) DT : $2.02B MRNA : $2.23B
Gross Profit (TTM) DT : $1.65B MRNA : -$309.00M
EBITDA (TTM) DT : $289.14M MRNA : -$3.02B

Return for Risk

DT vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DT

DT Risk / Return Rank: 19
DT Sharpe Ratio Rank: 16
DT Sortino Ratio Rank: 17
DT Omega Ratio Rank: 17
DT Calmar Ratio Rank: 22
DT Martin Ratio Rank: 22

MRNA

MRNA Risk / Return Rank: 78
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 79
MRNA Omega Ratio Rank: 75
MRNA Calmar Ratio Rank: 79
MRNA Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DT vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Dynatrace, Inc. (DT) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	DT	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.62	1.28	-1.91
Sortino ratio: Return per unit of downside risk	-0.68	2.13	-2.81
Omega ratio: Gain probability vs. loss probability	0.91	1.24	-0.33
Calmar ratio: Return relative to maximum drawdown	-0.58	2.34	-2.91
Martin ratio: Return relative to average drawdown	-1.01	4.59	-5.59

DT vs. MRNA - Sharpe Ratio Comparison

The current DT Sharpe Ratio is -0.62, which is lower than the MRNA Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of DT and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

DT vs. MRNA - Drawdown Comparison

The maximum DT drawdown since its inception was -61.77%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for DT and MRNA.

Drawdown Indicators

	DT	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-61.77%	-95.38%	+33.61%
Max Drawdown (1Y) Largest decline over 1 year	-42.87%	-35.51%	-7.36%
Max Drawdown (3Y) Largest decline over 3 years	-48.16%	-86.58%	+38.42%
Max Drawdown (5Y) Largest decline over 5 years	-61.77%	-95.38%	+33.61%
Current Drawdown Current decline from peak	-48.26%	-89.70%	+41.44%
Average Drawdown Average peak-to-trough decline	-30.74%	-57.06%	+26.32%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.41%	18.06%	+6.35%

Volatility

DT vs. MRNA - Volatility Comparison

The current volatility for Dynatrace, Inc. (DT) is 14.37%, while Moderna, Inc. (MRNA) has a volatility of 17.56%. This indicates that DT experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DT	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.37%	17.56%	-3.19%
Volatility (6M) Calculated over the trailing 6-month period	33.53%	48.82%	-15.29%
Volatility (1Y) Calculated over the trailing 1-year period	39.53%	64.75%	-25.22%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	40.76%	66.49%	-25.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	46.56%	72.15%	-25.59%

Dividends

DT vs. MRNA - Dividend Comparison

Neither DT nor MRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both DT and MRNA in my portfolio?

DT and MRNA have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, DT or MRNA?

MRNA has higher volatility (17.56%) compared to DT (14.37%). In terms of maximum drawdown, DT dropped -61.77% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.28 vs -0.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.